US Patent

US8334265 — Method of treatment of photodermatoses

Method of Use · Assigned to Clinuvel Pharmaceuticals Ltd · Expires 2033-01-20 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating photodermatoses by administering an alpha-MSH analogue to reduce skin photosensitivity.

USPTO Abstract

This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.

Drugs covered by this patent

Scenesse (AFAMELANOTIDE) · Clivunel Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2638`	—	Scenesse

Patent Metadata

Patent number: US8334265
Jurisdiction: US
Classification: Method of Use
Expires: 2033-01-20
Drug substance claim: No
Drug product claim: No
Assignee: Clinuvel Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.